Perioperative immunotherapy for hepatocellular carcinoma
10.3969/j.issn.1001-5256.2022.05.002
- VernacularTitle:肝癌围手术期的免疫治疗
- Author:
Bin XU
1
;
Meiling LI
1
;
Huichuan SUN
1
Author Information
1. Department of Liver Tumor Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China
- Publication Type:Discussions by Experts
- Keywords:
Carcinoma, hepatocellular;
Immunotherapy;
Neoadjuvant therapy;
Conversion therapy;
Adjuvant therapy
- From:
Journal of Clinical Hepatology
2022;38(5):980-984
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) greatly threatens the life and health of Chinese people. Most patients with HCC are already in the advanced stage when attending the hospital and are not eligible for radical treatment, and patients in the early stage of HCC who are eligible for radical treatment still face a high risk of recurrence after surgery. In recent years, immunotherapy based on immune checkpoint inhibitors (ICIs) has made great progress in the treatment of advanced HCC, and perioperative immunotherapy for HCC is attracting more and more attention. Immunotherapy in the perioperative period of HCC can improve the feasibility of hepatectomy, reduce the recurrence rate after hepatectomy, and prolong the survival of patients. This article discusses the application of ICIs-based immunotherapy in the perioperative period of HCC and the issues that need to be considered, so as to provide new ideas for perioperative immunotherapy for HCC.
